VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2015 | Biomarkers of cardiotoxicity in multiple myeloma

Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY talks about the biomarkers of cardiotoxicity in multiple myeloma (MM). In this new era of more efficient therapies, the medical community is focusing on improving the quality of life of MM patients. Recent research has shown the detrimental impact of certain therapies on the cardiovascular system. Prof. Landgren discusses the data presented at the American Society of Hematology (ASH) 2015 Annual Meeting by his group on cardio-oncology in MM.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter